STENTYS: Appointment of Cardiovascular Device Veteran as New CEO

- Christophe Lottin, ex second in command at stent company Hexacath, brings 20 years of sales and management experience
- Gonzague Issenmann recruited his successor to ensure the company he has created continues to thrive

PRINCETON, N.J. and PARIS – July 4, 2016 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the Board of Directors has appointed Christophe Lottin as the new Chief Executive Officer of the Company. Gonzague Issenmann has organized his succession and will ensure a smooth transition over the next quarter.

Christophe Lottin, who has twenty years of experience in cardiology, rose through the sales organization of Boston Scientific and Hexacath France, up to the position of President with responsibility for Benelux, Switzerland and Canada. In particular, he was instrumental in the commercial success of the Optimax coronary stent. In his multiple roles, he had to coordinate the critical departments of a stent company, such as R&D, Clinical and Regulatory affairs.

Gonzague Issenmann, co-founder of STENTYS, commented: "I am extremely proud of what we accomplished over the last 10 years with an amazing team. The Self-Apposing Technology, with numerous technical improvements and clinical milestones, is now world renowned. Today, STENTYS’ profile has evolved and Christophe is the person the Company needs to keep prospering commercially and become a major industry player. I wish him all the success that STENTYS deserves and remain a long term shareholder."

Christophe Lottin, Chief Executive Officer of STENTYS, added: "I am honored to assume the leadership of a company that has built a phenomenal reputation for itself in the cardiology community. As a long time cardiovascular device industry insider, I know how STENTYS products strong differentiation is a solid foundation to continue building the company and write a successful story."

Michel Darnaud, Chairman of the Board, concluded: "In the name of the Board, I would like to thank Gonzague for his relentless dedication to the company and for the strategic decisions that he has made. It is the sign of an astute entrepreneur to know when to pass the baton to a different profile of leader. I have known Christophe for years and can vouch for his credentials. The board is looking forward to this new phase of the Company’s life.”

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS' Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America.

More information is available at www.stentys.com

Safe Harbor Statements
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section

STENTYS
STNT
Euronext
PEA
PME

STENTYS
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap
Investor Relations / Strategic Communications
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 92
stentys@newcap.eu

STENTYS is listed on Compartiment C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT